Kenvue Inc

How Kenvue’s $1.5 billion talc verdict could reshape its finances, product strategy, and investor outlook amid tightening safety regulations.

How Kenvue’s indemnification strategy and Johnson & Johnson’s appeal reshape asbestos‑talc liability, consumer‑health risk, and industry safety standards.

Explore Kenvue’s quiet yet steady growth, financial health, and regulatory challenges—plus strategic insights on digital, ESG, and portfolio expansion in the consumer‑health space.

Kenvue Inc.’s credit outlook has been downgraded to ‘Negative’ by Moody’s, but the company’s robust market capitalization, diversified product portfolio, and continued bullish valuation by JP Morgan suggest its underlying business fundamentals remai…

Kenvue Inc., a consumer health company spun off from Johnson & Johnson, faces regulatory scrutiny over potential links between acetaminophen and autism, but its solid financials, diversified brand portfolio, and proactive cost-cutting initiatives pr…

Kenvue Inc., the maker of Tylenol, is navigating a high-profile regulatory scrutiny over alleged links between its pain-relief product and autism spectrum disorders, but its proactive engagement and comprehensive defense strategy have helped boost i…

Kenvue Inc.’s share price has surged in recent trading sessions, driven by a growing investor appetite for consumer-health equities and the company’s steady market momentum.

Kenvue Inc., the parent company of Tylenol, faces a financial crisis and plummeting stock prices after allegations surfaced linking Tylenol use by pregnant women to an increased risk of autism in their children.

Kenvue’s stock price has fluctuated significantly, with a 52-week high of $25.17 and low of $19.75, and valuation metrics suggest a mix of confidence and concern among investors.

Kenvue’s stock price has fluctuated within a narrow range, with a price-to-earnings ratio and price-to-book ratio indicating a significant premium to its book value.